Dr Leigh has previously served as chief medical officer for Paramount Biosciences. Dr Leigh has also held positions at Genentech, Idec Pharmaceuticals, and Biogen Idec where he was responsible for global clinical oncology development, managing multiple clinical stage programs and marketed products including Rituxan and Zevalin.
Dr Leigh holds a BS degree from University of California, Irvine in the field of biological sciences with a focus on Genetics, and a MD from the University of California, San Francisco School of Medicine.
Charles Theuer, president and CEO of Tracon, said: “Dr Leigh brings an extensive background in oncology development and proven leadership. He has successfully developed monoclonal antibodies and has the ability to lead highly productive teams – skills that will facilitate Tracon’s transition into a Phase II company.”